BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,550,000 shares, an increase of 9.4% from the December 31st total of 2,330,000 shares. Based on an average daily trading volume, of 806,600 shares, the days-to-cover ratio is currently 3.2 days.

BioNTech Price Performance

Shares of BNTX opened at $119.82 on Tuesday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a 50-day simple moving average of $117.33 and a 200-day simple moving average of $107.57. The company has a market capitalization of $28.73 billion, a price-to-earnings ratio of -57.06 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period last year, the company posted $0.73 earnings per share. On average, equities research analysts anticipate that BioNTech will post -3.77 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC purchased a new position in shares of BioNTech during the 2nd quarter worth $223,000. GAMMA Investing LLC lifted its stake in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares in the last quarter. Atomi Financial Group Inc. bought a new position in BioNTech during the 3rd quarter valued at $405,000. Perfromance Wealth Partners LLC bought a new position in BioNTech during the 3rd quarter worth approximately $238,000. Finally, Probity Advisors Inc. acquired a new position in shares of BioNTech in the 3rd quarter valued at about $216,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on BNTX shares. HC Wainwright reissued a “buy” rating and issued a $150.00 price target on shares of BioNTech in a report on Monday, November 18th. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. HSBC upped their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, Wells Fargo & Company initiated coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.